Jeremy Katzen is a Respiratory physician affiliated with Translational Therapeutics. OpenAlex indexes 89 publications with 2,947 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3737 Market St
10th Fl
Philadelphia, PA 191045545
Telephone
215-662-3202Registry record last updated 2 Apr 2019.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47.1%Kinase inhibitor36%Ofev100%Part D<11 patientsPyridone11%Pirfenidone100%Part D<11 patientsMetabolism & gastrointestinal
41.2%Corticosteroid33.1%Prednisone100%Part D<11 patientsProton pump inhibitor8.1%Omeprazole100%Part D<11 patientsRespiratory
11.8%beta2-Adrenergic Agonist11.8%Albuterol Sulfate Hfa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Alveolar Epithelial Stress Signaling in Lung Fibrosis
University of Pennsylvania
FY2026$667,795R01HL172975 - Deciphering the Molecular Mechanism of Pediatric Interstitial Lung Disease to Advance Targeted Therapies
University of Pennsylvania
FY2026$601,596R01HL176680 - Alveolar Epithelial Stress Signaling in Lung Fibrosis
University of Pennsylvania
FY2025$683,564R01HL172975
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Brem, MD
Translational Therapeutics
Rita Shaughnessy, MD
Translational Therapeutics
James Gugger
Translational Therapeutics
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”